Aurora Kinase

Aurora kinases are serine/threonine kinases that are essential for cell proliferation. Aurora kinase helps the dividing cell dispense its genetic materials to its daughter cells. More specifically, Aurora kinases play a crucial role in cellular division by controlling chromatid segregation. Defects in this segregation can cause genetic instability, a condition which is highly associated with tumorigenesis. Three Aurora kinases have been identified in mammalian cells to date, Aurora A, Aurora B, Aurora C. Besides being implicated as mitotic regulators, these three kinases have generated significant interest in the cancer research field due to their elevated expression profiles in many human cancers. The human Aurora kinases present a similar domain organization, with a N-terminal domain of 39 to 129 residues in length, a protein kinase domain and a short C-terminal domain containing 15 to 20 residues. The N-terminal domain of three proteins share low sequence conservation, which determines selectivity during protein-protein interactions.

Aurora Kinase Inhibitors

Alisertib
(MLN 8237)

Cat. No.: HY-10971

Alisertib (MLN 8237) is an orally active and selective **Aurora A kinase** inhibitor (IC_{50}=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.



Purity: 99.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AMG 900

Cat. No.: HY-13253

AMG 900 is a potent and highly selective **pan-Aurora** kinases inhibitor with IC_{50} of 5 nM, 4 nM and 1 nM for **Aurora A**, **B** and **C**, respectively.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (IC_{50}s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.61%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Aurora Kinase Inhibitor 3

Cat. No.: HY-112373

Aurora Kinase Inhibitor 3 is a strong and selective **Aurora A kinase** inhibitor with an IC_{50} of 42 nM, and weakly inhibits EGFR with an IC_{50}>10 μM.



Purity: 98.98%
Clinical Data:
Size: 10 mM × 1 mL, 1 mg, 5 mg

AZD1152
(Barasertib)

Cat. No.: HY-10127

AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective **Aurora B** inhibitor with IC_{50} of 0.37 nM in a cell-free assay.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Barasertib-HQPA
(AZD2811; INH-34; AZD1152-HQPA)

Cat. No.: HY-10126

Barasertib-HQPA (AZD2811) is a highly selective **Aurora B** inhibitor with an IC_{50} of 0.37 nM in a cell-free assay, and shows 3700-fold selectivity for Aurora B over Aurora A.



Purity: 99.47%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-847325

Cat. No.: HY-18955

BI-847325 is an ATP competitive dual inhibitor of **MEK** and aurora kinases (**AK**) with IC_{50} values of 4 and 15 nM for human MEK2 and AK-C, respectively.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT 137690

Cat. No.: HY-10804

CCT 137690 is a potent and orally available **aurora** kinase inhibitor with IC_{50}s of 15, 25, and 19 nM for aurora A, B and C, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT129202

Cat. No.: HY-12049

CCT129202 is an **aurora** kinase inhibitor with IC_{50}s of 42, 198, and 227 nM for aurora A, B and C, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CCT241736

Cat. No.: HY-18161

CCT241736 is a potent and orally bioavailable dual **FLT3** and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC_{50}, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Cenisertib

(AS-703569; R-763) Cat. No.: HY-13072

Cenisertib (AS-703569) is a multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC).



Purity: 99.56%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CYC-116

Cat. No.: HY-10558

CYC-116 is a potent **aurora A** and **aurora B** inhibitor with K_is of 8 and 9 nM, respectively.



Purity: 98.17%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg

Danusertib

(PHA-739358) Cat. No.: HY-10179

Danusertib is a pyrrolo-pyrazole and **aurora kinase** inhibitor with **IC_{50}** of 13, 79, and 61 nM for Aurora A, B, and C, respectively.



Purity: 99.44%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK-1070916

(GSK-1070916A) Cat. No.: HY-70044

GSK-1070916 is a potent and selective ATP-competitive inhibitor of **aurora B** and **aurora C** with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.



Purity: 99.55%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Hesperadin

Cat. No.: HY-12054

Hesperadin is an ATP competitive indolinone inhibitor of **Aurora A** and **B**. Hesperadin inhibits Aurora B with an **IC_{50}** of 250 nM.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hesperadin hydrochloride

Cat. No.: HY-12054A

Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of **Aurora A** and **B**. Hesperadin hydrochloride inhibits Aurora B with an **IC_{50}** of 250 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilorasertib

(ABT-348) Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with **IC_{50}**s of 1 nM, 7 nM, 120 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride) Cat. No.: HY-16018A

Ilorasertib hydrochloride (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with **IC_{50}**s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-7706621

Cat. No.: HY-10329

JNJ-7706621 is a potent **aurora kinase** inhibitor, and also inhibits **CDK1** and **CDK2**, with IC_{50}s of 9 nM, 3 nM, 11 nM, and 15 nM for **CDK1**, **CDK2**, **aurora-A** and **aurora-B**, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL^{T315I}** and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY3295668

(AK-01)

Cat. No.: HY-114258

LY3295668 (AK-01) is a potent, orally active and highly specific **Aurora-A kinase** inhibitor, with K_i values of 0.8 nM and 1038 nM for AurA and AurB, respectively.



Purity: 99.61%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-5108

(VX-689)

Cat. No.: HY-13252

MK-5108 is a highly potent and specific inhibitor of **Aurora A kinase** with an IC_{50} value of 0.064 nM.



Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-8745

Cat. No.: HY-13819

MK-8745 is an **aurora A** kinase inhibitor with an IC_{50} of 0.6 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MLN8054

Cat. No.: HY-10180

MLN8054 is a potent, selective and orally available **aurora A** kinase inhibitor with an IC_{50} of 4 nM.



Purity: 99.43%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NU6140

Cat. No.: HY-107419

NU6140 is a selective **CDK2-cyclin A** inhibitor (IC_{50}, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs. NU6140 also potently inhibits **Aurora A** and **Aurora B**, with IC_{50}s of 67 and 35 nM, respectively. Enhances the apoptotic effect, with anti-cancer activity.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-03814735

Cat. No.: HY-14574

PF-03814735 is a potent, orally available and reversible **aurora A** and **aurora B** inhibitor with IC_{50}s of 0.8 and 0.5 nM, respectively.



Purity: 99.82%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PHA-680632

Cat. No.: HY-10178

PHA-680632 is an **aurora** kinase inhibitor with IC_{50}s of 27, 135 and 120 nM for aurora A, B and C, respectively.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Reversine

Cat. No.: HY-14711

Reversine is a novel class of ATP-competitive **Aurora kinase** inhibitor with IC_{50}s of 400, 500 and 400 nM for **Aurora A**, **Aurora B** and **Aurora C**, respectively.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCH-1473759

Cat. No.: HY-10482

SCH-1473759 is an **aurora** inhibitor with IC_{50}s of 4 and 13 nM for aurora A and B, respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SCH-1473759 hydrochloride

Cat. No.: HY-10483

SCH-1473759 hydrochloride is an **aurora** inhibitor with IC_{50}s of 4 and 13 nM for aurora A and B, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SNS-314

(SNS-314 Mesylate)

Cat. No.: HY-12003

SNS-314 is a potent and selective **aurora** kinase inhibitor with IC_{50}s of 9, 31, and 6 nM for aurora A, B and C, respectively.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SP-96

Cat. No.: HY-131339

SP-96 is a highly potent, selective and non-ATP-competitive **Aurora B** (IC_{50}=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI_{50}=107 nM).



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-632

Cat. No.: HY-15767

TAK-632 is a potent **pan-RAF** inhibitor with IC_{50} of 1.4, 2.4 and 8.3 nM for **CRAF**, **$BRAF^{V600E}$**, **$BRAF^{WT}$**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TAK-901

Cat. No.: HY-12201

TAK-901 is a multi-targeted **aurora** inhibitor with IC_{50}s of 21 and 15 nM for aurora A and B, respectively.



Purity: 99.80%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

TCS7010

Cat. No.: HY-70061

TCS7010 is a potent and highly selective **Aurora A** inhibitor with with an IC_{50} of 3.4 nM.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tozasertib

(VX 680; MK-0457)

Cat. No.: HY-10161

Tozasertib (VX 680; MK-0457) is an inhibitor of **Aurora A/B/C kinases** with K_is of 0.6, 18, 4.6 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Tripolin A

((E)-Tripolin A)

Cat. No.: HY-124330

Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive **Aurora A kinase** inhibitor, with IC_{50} values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ZM-447439

Cat. No.: HY-10128

ZM-447439 is an **aurora** kinase inhibitor with **IC_{50}**s of 110 and 130 nM for aurora A and B, respectively.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg